Biophan Technologies Will Participate In SDForum's Nanotechnology Series' Session, `Nanotechnology & Biotechnology - The Next Wave'.Business Editors/Health/Medical Writers BIOWIRE2K ROCHESTER, N.Y.--(BUSINESS WIRE)--April 15, 2004 Biophan Technologies, Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). : BIPH BIPH Bogomoletz Institute of Physiology (National Academy of Sciences; Ukraine) ) an innovator, developer and marketer of MRI-related and other advanced biomedical technology, announced today that it will present at SDForum's Nanotechnology Series. Michael Weiner, Biophan's CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. , will present at the session entitled, "Nanotechnology & Biotechnology - The Next Wave," on Monday, April 19, 2004, at the George E. Pake Auditorium, located at the Xerox Palo Alto Research Center Palo Alto Research Center - XEROX PARC (PARC (Palo Alto Research Center Incorporated, Palo Alto, CA, www.parc.com) Founded in 1970, PARC is a Xerox subsidiary involved in high-tech research and development. Although Xerox's headquarters are in Stamford, Connecticut, and manufacturing and marketing are in Rochester, New York, PARC is ), in Palo Alto, CA. Biophan's technologies include filtering, shielding, coating, imaging, and photonic solutions to both MRI 1. (application) MRI - Magnetic Resonance Imaging. 2. MRI - Measurement Requirements and Interface. safety and MRI image compatibility. NanoView(TM), Biophan's newest technology, is intended to utilize nanomagnetic particles as contrast agents that preferentially bind to tissues of diagnostic interest, creating improved detail and contrast in images. Mr. Weiner will give an overview of this recently developed technology and other nanotechnology capabilities that may influence the biomedical bi·o·med·i·cal adj. 1. Of or relating to biomedicine. 2. Of, relating to, or involving biological, medical, and physical sciences. device industry in the near future. About Biophan Technologies Biophan Technologies develops and markets cutting-edge technologies designed to make biomedical devices--such as cardiac pacemakers, surgical and diagnostic tools--safe and compatible with magnetic resonance imaging magnetic resonance imaging (MRI), noninvasive diagnostic technique that uses nuclear magnetic resonance to produce cross-sectional images of organs and other internal body structures. (MRI) equipment. The technology is also designed to create enhanced MRI contrast agents. Committed to growth through innovation and developmental leadership, Biophan and its licensors have four issued U.S. patents and over 50 patents pending, in areas including nanomagnetic particle coatings, radio frequency filters, polymer composites, and photonics. Biophan's goal is to develop and implement technology that will one day make all biomedical devices capable of safely and successfully working with MRI. For more information, please visit www.biophan.com. About the SDForum SDForum is the leading Silicon Valley not-for-profit organization providing an unbiased source of information and insight to the technology community for 20 years. This session is open to the public. For more information and to register for this session, please visit http://www.sdforum.org. Safe Harbor Statement: Certain statements included in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors including, but not limited to: the development of the Company's MRI technologies; the approval of the Company's patent applications; the successful implementation of the Company's research and development programs; the acceptance by the market of the Company's products; competition and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in the Company's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with the Company's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances. |
|
||||||||||||||

Printer friendly
Cite/link
Email
Feedback
Reader Opinion